Evidence map›Paper›PMID 34767126›Full record

ArticleBiotechnology letters2022

Proton-transfer-reaction mass spectrometry (PTR-MS) for online monitoring of glucose depletion and cell concentrations in HEK 293 gene therapy processes.

Benjamin Bayer, Andreas Maccani, Johanna Jahn, Mark Duerkop, Ewald Kapeller, Robert Pletzenauer, Barbara Kraus, Gerald Striedner, Juan A Hernandez Bort

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Benjamin BayerNovasign GmbH, Vienna, Austria.
Andreas MaccaniGene Therapy Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies, Uferstraße 15, 2304, Orth an der Donau, Austria.
Johanna JahnGene Therapy Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies, Uferstraße 15, 2304, Orth an der Donau, Austria.
Mark DuerkopNovasign GmbH, Vienna, Austria.
Ewald KapellerGene Therapy Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies, Uferstraße 15, 2304, Orth an der Donau, Austria.
Robert PletzenauerGene Therapy Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies, Uferstraße 15, 2304, Orth an der Donau, Austria.
Barbara KrausGene Therapy Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies, Uferstraße 15, 2304, Orth an der Donau, Austria.
Gerald StriednerNovasign GmbH, Vienna, Austria.
Juan A Hernandez BortGene Therapy Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies, Uferstraße 15, 2304, Orth an der Donau, Austria. juan.hernandezbort@takeda.com.ORCID http://orcid.org/0000-0003-2348-4864
Mundipharma (United Kingdom) · GBBOKU University · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe applicability of proton-transfer-reaction mass spectrometry (PTR-MS) as a versatile online monitoring tool to increase consistency and robustness for recombinant adeno-associated virus (rAAV) producing HEK 293 bioprocesses was evaluated. We present a structured workflow to extract process relevant information from PTR-MS data.

resultsReproducibility of volatile organic compound (VOC) measurements was demonstrated with spiking experiments and the process data sets used for applicability evaluation consisted of HEK 293 cell culture triplicates with and without transfection. The developed data workflow enabled the identification of six VOCs, of which two were used to develop a soft sensor providing better real-time estimates than the conventional capacitance sensor. Acetaldehyde, another VOC, provides online process information about glucose depletion that can directly be used for process control purposes.

conclusionsThe potential of PTR-MS for HEK 293 cell culture monitoring has been shown. VOC data derived information can be used to develop soft sensors and to directly set up new process control strategies.

Indexed as

ProtonsVolatile Organic CompoundsGenetic TherapyGlucoseHEK293 CellsHumansMass SpectrometryReproducibility of ResultsGlucoseProtonsVolatile Organic CompoundsBiomass soft sensorCell culture PATGlucose online monitoringHEK 293 cell culture monitoringPTR-MS monitoringrAAV process

Identifiers

PMID34767126
PMCPMC8854141
OpenAlexW3211433163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.